Form 4: Director Ezra Friedberg Executes Tax-Related Stock Sale

Director Ezra Friedberg sold 144 shares of Pelthos Therapeutics Inc. to satisfy tax obligations related to RSU vesting.

Summary

• Director Ezra Friedberg disposed of 144 shares of common stock on May 14, 2026.
• The transaction was executed at a weighted average price of $27.007 per share.
• The sale was conducted under a pre-established Rule 10b5-1 trading plan adopted on December 16, 2025.
• The purpose of the sale was to cover tax withholding obligations resulting from the vesting of restricted stock units.
• Following the transaction, the director maintains direct ownership of 81,883 shares and indirect ownership of 122,072 shares through affiliated entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative action for tax compliance rather than a strategic market move.

Positives

• The transaction was pre-planned under a Rule 10b5-1 plan, indicating adherence to corporate governance best practices.
• The sale was strictly for tax compliance purposes rather than a discretionary divestment of equity.

Negatives

• The transaction represents a reduction in the director's direct equity stake in the company.

Risks

• Reliance on Rule 10b5-1 plans does not eliminate market volatility risks for the issuer's stock price.

Future Outlook

No forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person confirms the sale was made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, to satisfy tax obligations.

Industry Context

StockSavvy.ai notes that routine tax-related sales by directors are standard corporate practice and generally do not signal a change in management sentiment regarding the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to manage tax liabilities while avoiding potential insider trading concerns.

Related Party Transactions

• The reporting person is the manager of Balmoral Financial Group LLC and Key Recovery Group LLC, which hold 82,072 and 40,000 shares respectively.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was small and pre-planned.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Pelthos Therapeutics, PTHS, Insider Trading, Form 4, Equity Compensation, Rule 10b5-1